Non-Small Cell Lung Cancer Archives

There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.

Lung Cancer Treatment May Impact Daily Function in Older Adults

October 12, 2021

Older adults with lung cancer may experience declines in life-space mobility during treatment, according to a study published.

Lung Cancer

Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer

By

Sucharita Mistry, PhD

September 28, 2021

Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.

Lung Cancer

Adding Immunotherapy to Chemo Improves Survival in Metastatic Non-Small Cell Lung Cancer

By

Jonathan Goodman, MPhil

September 24, 2021

The combinations conferred benefits in nonsquamous non-small cell lung cancer only.

Lung Cancer

Tumor Microenvironment Predicts Efficacy of PD-1/PD-L1 Blockade in Non-Small Cell Lung Cancer

By

Sucharita Mistry, PhD

September 23, 2021

Response and survival outcomes differed according to the tumor microenvironment.

Lung Cancer

Type of Surgery and Surgical Pathway Tied to Risk of Perioperative COVID-19 in Non-Small Cell Lung Cancer

By

Jonathan Goodman, MPhil

September 21, 2021

Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.

Lung Cancer

Smoking Cessation Improves Survival Outcomes for Patients With Non-Small Cell Lung Cancer

By

Vicki Moore, PhD

September 17, 2021

Researchers found links between smoking cessation and survival outcomes among patients who were smokers at the time of non-small cell lung cancer diagnosis.

Lung Cancer

Unmet Care Needs, Financial Burden Are Concerns for Patients With mNSCLC Treated With Immunotherapy

By

Jessica Nye, PhD

September 15, 2021

A survey on supportive care needs revealed patients’ concerns regarding declining physical abilities, loved ones’ worries, and financial burdens.

Lung Cancer

Sintilimab Plus Chemo Prolongs Survival in Advanced Non-Small Cell Lung Cancer

By

Sucharita Mistry, PhD

September 10, 2021

The median overall survival was not reached at a median follow-up of 22.9 months.

Metformin did not improve progression-free or overall survival in either study.

Lung Cancer

Metformin Fails to Show Benefit in Non-Small Cell Lung Cancer Trials

By

Jon Kelvey

August 12, 2021

Metformin did not improve progression-free or overall survival in either study.

Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.

Lung Cancer

Atezolizumab Gets Priority Review as Adjuvant Treatment for Early NSCLC

By

Brian Park, PharmD

August 9, 2021

The sBLA is supported by data from the IMpower010 study that compared atezolizumab with best supportive care in 1005 adults with Stage IB-IIIA NSCLC after resection and adjuvant chemotherapy.